Skip to main content

ResApp deal dips on test results

21/06/2022 - 11:47

Bookmark

Save articles for future reference.

Pfizer takeover target ResApp has had its valuation cut after its COVID-19 detecting cough tool failed to meet performance requirements needed to lock in an improved all-cash offer for the business.

X

To read our articles you will need to either login or subscribe.